In vivo crosslinkable hydrogels containing gold nanoparticles for medical applications

By using a covalent cross-linking system of reactive polymers, multifunctional compounds, and gold nanoparticles, a stable radiopaque hydrogel is formed, solving the problem of rapid decomposition of existing hydrogels and achieving long-term radiation impermeability and cross-linking density, making it suitable for a variety of medical applications.

CN123076408APending Publication Date: 2026-11-10BOSTON SCIENTIFIC SCIMED INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202580028179.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-04-15
Filing Date
2025-04-14
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing radiopaque hydrogels decompose rapidly in vivo, making it difficult to maintain long-term radiopaqueness and cross-linking density.

Method used

A system comprising reactive polymers, reactive multifunctional compounds, and gold nanoparticles is used to form a radiopaque crosslinked hydrogel through covalent crosslinking. The gold nanoparticles are retained in the hydrogel through non-covalent interactions, enhancing its stability and radiation opacity.

Benefits of technology

It achieves long-term radiation impermeability and cross-linking density within a biodegradation time of 1 day to 5 years, making it suitable for a variety of medical applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123076408A_ABST
    Figure CN123076408A_ABST
Patent Text Reader

Abstract

In some aspects, this disclosure relates to systems comprising: (a) a reactive polymer comprising a plurality of first hydrophilic polymer segments and a plurality of first reactive moieties; (b) a reactive multifunctional compound comprising a plurality of second reactive moieties; and (c) gold nanoparticles functionalized with a plurality of second hydrophilic polymer segments. In other aspects, this disclosure relates to crosslinked reaction products formed by such systems. In a further aspect, this disclosure relates to therapeutic methods using these systems and such crosslinked reaction products.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This application claims the benefit of U.S. Provisional Patent Application No. 63 / 633,927, filed April 15, 2024, the disclosure of which is incorporated herein by reference. Technical Field

[0003] This disclosure relates to radiopaque hydrogels and crosslinkable systems for forming radiopaque hydrogels, among other aspects. The radiopaque hydrogels and the crosslinkable systems for forming such radiopaque hydrogels can be used in, for example, a variety of medical applications. Background Technology

[0004] SpaceOAR® is a rapidly crosslinked hydrogel that polymerizes in vivo within seconds. It is based on a multi-arm polyethylene glycol (PEG) polymer with a polyol core, functionalized with succinimidyl glutarate as a reactive end group, which then reacts with trilysine to form a crosslink. This product has become a highly successful clinical biomaterial in prostate cancer treatment. A further improvement to this structure is the functionalization of a portion of the succinimidyl glutarate end group with a 2,3,5-triiodobenzamide group, thereby providing radiopacity. This hydrogel, known by the trade name SpaceOAR Vue®, is a radiopaque version of SpaceOAR® for prostate medical applications. Above a specific pH, the succinimidyl glutarate groups react rapidly in vivo with a trilysine crosslinking agent to form the hydrogel. The hydrogel decomposes in vivo within approximately 6–9 months. This decomposition primarily occurs through the hydrolysis of ester linkages on the glutarate groups. Summary of the Invention

[0005] This disclosure provides alternative systems for forming hydrogels (including iodine-free hydrogels) while maintaining or improving crosslinking density and / or radiation impermeability. As used herein, a "hydrogel" (also referred to herein as a "crosslinked hydrogel") is a crosslinked polymer that contains water or can absorb water but does not dissolve when placed in water.

[0006] In some aspects, this disclosure relates to systems comprising: (a) a reactive polymer comprising a plurality of first hydrophilic polymer segments and a plurality of first reactive moieties; (b) a reactive multifunctional compound comprising a plurality of second reactive moieties; and (c) gold nanoparticles functionalized with a plurality of second hydrophilic polymer segments.

[0007] In some embodiments, the reactive polymer is a multi-arm polymer comprising three or more polymer arms connected to a core region, each arm comprising one of the first hydrophilic polymer segments and one of the first reactive portions.

[0008] In some embodiments that can be used in conjunction with the above aspects and embodiments, the reactive polymer is a multi-arm polymer comprising three or more polymer arms connected to a core region, each arm comprising cyclic anhydride residues located between a first hydrophilic polymer segment and a first reactive portion.

[0009] In some embodiments that can be used in conjunction with the above aspects and embodiments, the first hydrophilic polymer segment is selected from poly(epoxyalkylene) segments, polysaccharide segments, polyoxazoline segments, polydioxanone segments, polypeptide segments, and polyvinyl alcohol segments.

[0010] In some embodiments that can be used in conjunction with the above aspects and embodiments, each of the first hydrophilic polymer segments contains 10 to 1000 monomer residues.

[0011] In some embodiments that can be used in conjunction with the above aspects and implementation schemes, the maximum size of the gold nanoparticles is in the range of 1 nm to 2 micrometers.

[0012] In some embodiments that can be used in conjunction with the above aspects and embodiments, the second hydrophilic polymer segment is selected from poly(epoxyalkylene) segments, polysaccharide segments, polyoxazoline segments, polydioxanone segments, polypeptide segments, and polyvinyl alcohol segments.

[0013] In some embodiments that can be used in conjunction with the above aspects and embodiments, the second reactive portion is linked to a polyol residue or a polycarboxylic acid residue.

[0014] In some embodiments that can be used in conjunction with the above aspects and implementation schemes, the second reactive portion is linked to the polyfunctional compound via a hydrolyzable ester group.

[0015] In some embodiments that can be used in conjunction with the above aspects and embodiments, the first reactive portion comprises a cyclic imide ester group, and the second reactive portion comprises a primary amine group, a thiol group, or a hydroxyl group.

[0016] In some embodiments that can be used in conjunction with the above aspects and embodiments, the first reactive portion comprises a primary amine group, a thiol group, or a hydroxyl group, and the second reactive portion comprises a cyclic imide ester group.

[0017] In some embodiments that can be used in conjunction with the above aspects and embodiments, the first reactive portion comprises a strained alkynyl group, and the second reactive portion comprises an azide group.

[0018] In some embodiments that can be used in conjunction with the above aspects and embodiments, the first reactive portion comprises an azide group, and the second reactive portion comprises a strained alkynyl group.

[0019] In some embodiments that can be used in conjunction with the above aspects and embodiments, the first reactive portion comprises a tonicene group, and the second reactive portion comprises a tetrazine group.

[0020] In some embodiments that can be used in conjunction with the above aspects and embodiments, the first reactive portion comprises a tetrazine group, and the second reactive portion comprises a torinyl group.

[0021] In some embodiments that can be used in conjunction with the above aspects and implementations, the system also includes a delivery device.

[0022] In other respects, this disclosure provides a treatment method comprising administering to a subject a mixture comprising a reactive polymer, a multifunctional compound, and gold nanoparticles according to any of the foregoing aspects and embodiments, wherein the reactive polymer and the multifunctional compound are crosslinked after application to form a hydrogel, wherein the gold nanoparticles are retained in the hydrogel by non-covalent interactions.

[0023] In some embodiments, the method includes administering to a subject a first fluid composition comprising the reactive polymer and a second fluid composition comprising the multifunctional compound, wherein the gold nanoparticles are provided in the first fluid composition, the second composition, or both.

[0024] In some embodiments, the method includes administering to a subject a first fluid composition comprising the reactive polymer and the multifunctional compound, and a second fluid composition comprising an accelerator for accelerating covalent crosslinking formation, wherein the gold nanoparticles are provided in the first fluid composition, the second composition, or both.

[0025] In some of these embodiments, a dual-tube syringe is used to deliver the first fluid composition and the second fluid composition.

[0026] In other respects, this disclosure relates to crosslinked hydrogels in which gold nanoparticles according to any of the foregoing aspects and embodiments are retained in the crosslinking reaction products of reactive polymers and multifunctional compounds according to any of the foregoing aspects and embodiments.

[0027] In some embodiments, the cross-linked hydrogel is in the form of injectable particles.

[0028] In some embodiments that can be used in conjunction with the foregoing aspects and embodiments, the crosslinked hydrogel comprises a hydrolyzable bonded structure, and the crosslinked hydrogel is bioerode in vivo over a period of 1 day or less to 5 years or longer (e.g., ranging from 1 day to 3 days to 1 week to 2 weeks to 1 month to 6 months to 1 to 2 to 5 years or longer (in other words, within a period of time between any two of the foregoing values)).

[0029] In other respects, this disclosure relates to treatment methods comprising administering to a subject any of the foregoing aspects and implementation methods a radiopaque cross-linked hydrogel composition.

[0030] The above and other aspects, implementations, features and benefits of this disclosure will become apparent from the following detailed description. Attached Figure Description

[0031] Figure 1 A reactive multi-arm polymer according to one embodiment of the present disclosure is schematically shown.

[0032] Figure 2 A method for forming functionalized gold nanoparticles according to one embodiment of the present disclosure is illustrated schematically.

[0033] Figures 3A-3D Methods for forming reactive polymers according to four embodiments of the present disclosure are illustrated schematically.

[0034] Figures 4A-4C The methods for forming covalently bonded structures according to three embodiments of the present disclosure are illustrated schematically.

[0035] Figure 5 The present invention schematically illustrates a method for forming a crosslinked product by covalently linking a reactive multi-arm polymer and a reactive multifunctional compound in the presence of functionalized gold nanoparticles, according to one embodiment of the present disclosure.

[0036] Figure 6 A delivery device according to one embodiment of the present disclosure is shown.

[0037] Figure 7 A delivery device according to another embodiment of this disclosure is shown. Detailed Implementation

[0038] In some embodiments, the system comprises: (a) a reactive polymer comprising a plurality of first hydrophilic polymer segments and a plurality of first reactive moieties, (b) a reactive multifunctional compound comprising a plurality of second reactive moieties, and (c) gold nanoparticles functionalized with a polymer having second hydrophilic polymer segments.

[0039] In various embodiments, the system is configured to deliver the reactive polymer, the reactive multifunctional compound, and the gold nanoparticles under conditions that form a covalent crosslink between a first reactive portion of the reactive polymer and a second reactive portion of the reactive multifunctional compound, thereby forming a hydrogel in which gold nanoparticles are embedded.

[0040] Specific examples of the first reactive portion and the second reactive portion include, in particular, the following: (a) a first reactive portion containing an electrophilic group and a second reactive portion containing a nucleophilic group, or vice versa; (b) a first reactive portion containing a strainyne group and a second reactive portion containing an azide group, or vice versa; and (c) a first reactive portion containing a strainyne group and a second reactive portion containing a tetrazinyl group, or vice versa.

[0041] Now refer to Figure 1 The reactive polymer according to this disclosure includes a reactive multi-arm polymer 110, which includes a plurality of polymer arms connected to a core region 112, at least a portion of the polymer arms including hydrophilic polymer segments 114. One end of the hydrophilic polymer segment 114 is covalently connected to the core region 112 by a suitable bond, and the other end of the hydrophilic polymer segment 114 is covalently connected to a first reactive portion R1 by a suitable bond.

[0042] In some embodiments, at least a portion of the polymer arm comprises a hydrophilic polymer segment having a first end and a second end, a cyclic anhydride residue having a first end and a second end, and a reactive portion covalently attached to the second end of the cyclic anhydride residue, wherein the first end of the hydrophilic polymer segment is covalently attached to a core region, and the first end of the cyclic anhydride residue is covalently attached to the second end of the hydrophilic polymer segment.

[0043] The reactive polymers according to this disclosure include polymers having 3 to 100 arms, for example, any value in the range of 3 to 4 to 5 to 6 to 7 to 8 to 9 to 10 to 11 to 12 to 15 to 20 to 25 to 50 to 75 to 100 arms (in other words, having a number of arms ranging from any two of the aforementioned values).

[0044] The first reactive moiety R1 includes: a moiety containing an electrophilic group, a moiety containing a nucleophilic group, a moiety containing a strained alkynyl group, a moiety containing a strained alkenyl group, and a moiety containing an azide group. The portion containing tetraazine group The part.

[0045] The electrophilic group can be selected from, for example, cyclic imide ester groups (e.g., succinimide ester groups, Maleimide ester group, glutarimide ester group, diethylene glycol imide ester group, phthalimide ester group and bicyclic [2.2.1]hept-5-ene-2,3-dicarboxylic acid imide ester group, The nucleophilic group can be selected from, for example, an amino group, a mercapto group, and a benzotriazole group, etc. The strained alkynyl group can be selected from, for example, (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl. And dibenzocyclooctyne group, as well as other possible groups. The tonicenyl group can be selected from, for example, cyclooct-4-en-1-yl. Cyclooct-4-enyl 2,5-dioxopyrrolidone-1-yl carbonate, N-(3-aminopropyl)-4-cyclooctene-1-yl ester of carbamate, or N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-4-cyclooctene-1-yl ester of carbamate, and other possible groups.

[0046] Electrophilic, nucleophilic, strainyne, strainene, azide, or tetrazinyl groups can be attached to the hydrophilic polymer segment 114 via any suitable linking portion. The linking portion can be selected from, for example, bonds, alkyl-containing linking portions, ether-containing linking portions, ester-containing linking portions, amide-containing linking portions, amino-containing linking portions, carbonate-containing linking portions, urethane-containing linking portions, urea-containing linking portions, or combinations of two or more of the aforementioned groups. In various embodiments, the linking portion comprises a hydrolyzable ester group.

[0047] The hydrophilic polymer segments can be selected from a variety of synthetic, natural, or synthetic-natural hybrid hydrophilic polymer segments. Examples of hydrophilic polymer segments include those formed from one or more hydrophilic monomers selected from: C1-C6-epoxides (e.g., ethylene oxide, propylene oxide, tetramethylene oxide, etc.), polar aprotic vinyl monomers (e.g., N-vinylpyrrolidone, acrylamide, N-methacrylamide, dimethacrylamide, N-vinylimidazolium, 4-vinylimidazolium, sodium 4-vinylbenzenesulfonate, etc.), dioxanone, and ester monomers (e.g., glycolide, lactide, β-propiolactone, β-butyrolactone, γ-butyrolactone). lactones, γ-valerolactone, δ-valerolactone, ε-caprolactone, etc.), oxazoline monomers (e.g., oxazoline and 2-alkyl-2-oxazoline, such as 2-(C1-C6 alkyl)-2-oxazoline, including various isomers such as 2-methyl-2-oxazoline, 2-ethyl-2-oxazoline, 2-n-propyl-2-oxazoline, 2-isopropyl-2-oxazoline, 2-n-butyl-2-oxazoline, 2-isobutyl-2-oxazoline, 2-hexyl-2-oxazoline, etc.), 2-phenyl-2-oxazoline, N-isopropylacrylamide, amino acids and sugars.

[0048] The hydrophilic polymer segments can be selected from, for example, the following polymer segments: polyether segments, including poly(C1-C6-epoxyalkylene) segments, such as poly(ethylene oxide) (PEO) (also known as polyethylene glycol or PEG) segments, poly(propylene oxide) segments, and poly(ethylene oxide-co-propylene oxide) segments; polymer segments formed from one or more polar aprotic vinyl monomers, including poly(N-vinylpyrrolidone) segments, poly(acrylamide) segments, poly(N-methacrylamide) segments, poly(dimethacrylamide) segments, poly(N-vinylimidazolium) segments, poly(4-vinylimidazolium) segments, and poly(sodium 4-vinylbenzenesulfonate) segments; poly(p-dioxane) segments; polyester segments, including polyglycolic acid segments, polylactic acid segments, poly(lactic acid-co-glycolic acid) segments, and poly(β-... Proprolol) segments, poly(β-butyrolactone) segments, poly(γ-butyrolactone) segments, poly(γ-valerolactone) segments, poly(δ-valerolactone) segments, and poly(ε-caprolactone) segments; polyoxazoline segments, including poly(2-C1-C6-alkyl-2-oxazoline) segments, such as poly(2-methyl-2-oxazoline) segments, poly(2-ethyl-2-oxazoline) segments, poly(2-propyl-2-oxazoline) segments, poly(2-isopropyl-2-oxazoline) segments, poly(2-n-butyl-2-oxazoline) segments, poly(2-phenyl-2-oxazoline) segments, poly(N-isopropylacrylamide) segments, polypeptide segments, and polysaccharide segments. Polysaccharide segments include those containing one or more uronic acid substances, such as galacturonic acid, glucuronic acid, and / or iduronic acid. Specific examples of polysaccharide segments include alginic acid, hyaluronic acid, pectin, agar, carrageenan, gellan gum, gum arabic, guar gum, xanthan gum, and carboxymethyl cellulose moieties.

[0049] Polymer segments used in the multi-arm polymers of this disclosure typically contain 10 or fewer monomer units to 1,000 or more monomer units, for example, ranging from 5 to 10 to 20 to 50 to 100 to 200 to 500 to 1,000 to 2,000 or more monomer units.

[0050] In some embodiments, the core region includes residues of a polyhydroxy compound (also referred to herein as a "polyol") containing three or more hydroxyl groups for forming the polymer arm. In some advantageous embodiments, the core region comprises residues of a polyol containing 3 to 100 hydroxyl groups.

[0051] Exemplary polyols may be selected from, for example, straight-chain, branched, and cyclic aliphatic polyols (including straight-chain, branched, and cyclic polyhydroxy alkanes), straight-chain, branched, and cyclic polyhydroxy ethers (including polyhydroxy polyethers), straight-chain, branched, and cyclic polyhydroxy alkyl ethers (including polyhydroxy alkyl polyethers), straight-chain, branched, and cyclic sugars and sugar alcohols (e.g., glycerol, mannitol, sorbitol, inositol, xylitol, styraxyl alcohol, threitol, arabinol, erythritol, pentaerythritol, dipentaerythritol, tripentaerythritol, arabinol, hexaglycerol, galactitol, fucose, ribose, arabinose, xylose, etc.). Polyols include threose, rhamnose, galactose, glucose, fructose, sorbitol, mannose, pyranose, atroose, tarose, tagatose, pyranoside, sucrose, lactose, and maltose; polymers of linear, branched, and cyclic sugars and sugar alcohols (defined herein as two or more units) (including oligomers of linear, branched, and cyclic sugars and sugar alcohols (defined herein as two to ten units, including dimers, trimers, tetramers, pentamers, hexamers, heptomers, octamers, nonamerms, and decamers); sugars and sugar alcohols include the aforementioned sugars and sugar alcohols, starch, amylose, dextrin, cyclodextrin, and polyhydroxy crown ethers and polyhydroxyalkyl crown ethers). Exemplary polyols also include aromatic polyols (including 1,1,1-tris(4'-hydroxyphenyl)alkanes, such as 1,1,1-tris(4-hydroxyphenyl)ethane and 2,6-bis(hydroxyalkyl)cresol, etc.).

[0052] Exemplary polyols also include polyhydroxylated polymers. For example, in some embodiments, the core region comprises polyhydroxylated polymer residues, such as polyvinyl alcohol residues, polyallyl alcohol, hydroxyethyl polyacrylate residues, or hydroxyethyl polymethacrylate residues. The length of such polyhydroxylated polymer residues can range, for example, from 3 to 100 monomer units.

[0053] In other embodiments, the core region comprises a silsesquioxane, which is a compound having a cage-like silicon-oxygen core composed of a Si-O-Si bonded structure and tetrahedral Si vertices. -H groups or external organic groups may be covalently attached to the cage-like silicon-oxygen core. In this disclosure, the organic groups comprise polymer arms. Silsesquioxanes used in this disclosure include silsesquioxanes with 6 silicon vertices, silsesquioxanes with 8 silicon vertices, silsesquioxanes with 10 silicon vertices, and silsesquioxanes with 12 silicon vertices, which can be used as the core of 6-arm, 8-arm, 10-arm, and 12-arm polymers, respectively. The silicon-oxygen core is sometimes referred to as T6, T8, T... 10 and T 12 A cage-like silicon-oxygen core (where T = the number of tetrahedral Si vertices). In all cases, each Si atom is bonded to three O atoms, and the oxygen atoms are in turn bonded to other Si atoms. Silsesquioxanes include those with the chemical formula [RsiO]. 3 / 2 ] nCompounds, where n is an integer of at least 6, typically 6, 8, 10, or 12 (thus having T6, T8, T... respectively). 10 or T 12 The T8 cage-like siloxane core (RiOi) is selected from a series of organic functional groups, such as alkyl, aryl, alkoxy, and polymer arms. The T8 cage-like siloxane core has been extensively studied and has the formula [RiOi]. 3 / 2 ]8, or equivalently R8Si8O 12 The structure is as follows: In this disclosure, the R group includes the polymer arm described herein.

[0054] The reactive multi-arm polymers according to this disclosure can be formed from hydroxyl-terminated precursor multi-arm polymers having arms comprising one or more hydroxyl terminal groups. In some of these embodiments, the hydroxyl-terminated precursor multi-arm hydrophilic polymer can react with cyclic anhydrides to form acid-terminated precursor polymers, wherein the carboxylic acid terminal group is attached to the hydrophilic polymer segment via a hydrolyzable ester group. For example, the terminal hydroxyl groups of the hydrophilic polymer segment can react with cyclic anhydrides (e.g., glutaric anhydride, succinic anhydride, malonic anhydride, adipic anhydride, diethylene glycol anhydride, etc.) to form acid-terminated segments, such as glutaric acid-terminated segments, succinic acid-terminated segments, malonic acid-terminated segments, adipic acid-terminated segments, diethylene glycol-terminated segments, etc.

[0055] The aforementioned cyclic anhydrides can react with hydroxyl-terminated precursor multi-arm hydrophilic polymers under alkaline conditions to form carboxylic acid-terminated precursor polymers containing carboxylic acid end groups, which are connected to hydrophilic polymer segments via hydrolyzable ester groups.

[0056] Now refer to Figures 3A-3C Cyclic anhydrides (specifically glutaric anhydride 312) react with hydroxyl-terminated precursor multi-arm hydrophilic polymers (specifically hydroxyl-terminated precursor multi-arm polyethylene oxide (PEO) 310, where R corresponds to the nucleus) to form acid-terminated multi-arm polymers (specifically glutaric acid-terminated multi-arm polyethylene oxide (PEO) 314). (Note that although in Figures 3A-3C And the following description Figure 3D In the diagram, only one arm of the multi-armed polyethylene oxide 310 is shown attached to the core R; however, it should be understood that other polymer arms exist. Figures 3A-3D In this context, n is an integer and can have values ​​ranging from 5 to 1000 or greater.

[0057] The reactive portion can then be attached to a carboxylic acid-terminated precursor polymer. In some embodiments, the electrophilic portion can be attached to the carboxylic acid-terminated precursor polymer. For example, N-hydroxycyclic imide compounds (e.g., N-hydroxysuccinimide, N-hydroxymaleimide, N-hydroxyglutarimide, N-hydroxyphthalimide, or N-hydroxy-5-norbornene-2,3-dicarboxylic acid imide, also known as N-hydroxybicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid imide (HONB), etc.) can be coupled in a suitable coupling agent (e.g., a carbodiimide coupling agent, such as N,N'-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethyl'-2-dicarboxylic acid imide, etc.) to ... In the presence of propylcarbodiimide (EDC), N-hydroxybenzotriazole (HOBt), BOP reagent, and / or other coupling agents, a precursor polymer capped with a carboxylic acid reacts to form an activated ester group (specifically a cyclic imide ester group (e.g., succinimide, maleimide, glutarimide, phthalimide, diethylene glycol imide, bicyclic [2.2.1]hept-5-ene-2,3-dicarboxylic acid imide, etc.)), which is attached to a hydrophilic polymer segment via a hydrolyzable ester group. In this way, many reactive diester groups can be formed.

[0058] For example, in the specific case of N-hydroxysuccinimide as an N-hydroxycyclic imide compound, exemplary reactive end groups include succinimide malonate group, succinimide glutarate group, succinimide succinate group, succinimide adipate group, and succinimide diethylene glycol ester group, etc. In the specific case of HONB as an N-hydroxy cyclic imide compound, exemplary reactive end groups include bicyclic [2.2.1]hept-5-ene-2,3-dicarboxylic acid imide malonic acid ester group, bicyclic [2.2.1]hept-5-ene-2,3-dicarboxylic acid imide glutarate ester group, bicyclic [2.2.1]hept-5-ene-2,3-dicarboxylic acid imide succinate ester group, bicyclic [2.2.1]hept-5-ene-2,3-dicarboxylic acid imide adipic acid ester group, and bicyclic [2.2.1]hept-5-ene-2,3-dicarboxylic acid imide diglycol ester group, etc. In the specific case where N-hydroxymaleimide is an N-hydroxy cyclic imide compound, exemplary reactive end groups include maleimide malonate groups, maleimide glutarate groups, maleimide succinate groups, maleimide adipate groups, and maleimide diethylene glycol ester groups, etc. In the specific case where N-hydroxyphthalimide is an N-hydroxycyclic imide compound, exemplary reactive end groups include phthalimide malonate group, phthalimide glutarate group, phthalimide succinate group, phthalimide adipate group, and phthalimide diglycol ester group, etc.

[0059] exist Figure 3A In the specific embodiment shown, glutaric acid-terminated multi-arm PEO 314 reacts with N-hydroxysuccinimide 316 in the presence of a coupling agent to form succinimide-glutaric acid-terminated multi-arm PEO 318.

[0060] In some embodiments, the primary amine group can be attached to a carboxylic acid-terminated precursor polymer. For example, a diamine compound (e.g., 1,2-diaminoethane, 1,3-diaminopropane, 1,4-diaminobutane, etc., wherein one of the amino groups is protected by a suitable protecting group (e.g., tert-butoxycarbonyl (tBoc) or fluorenylmethoxycarbonyl (Fmoc) or benzyloxycarbonyl (Cbz) protecting group)) can be attached to a carboxylic acid-terminated precursor polymer (e.g., ...) in the presence of a suitable coupling agent (e.g., a carbodiimide coupling agent). Figure 3AThe carboxylic acid group of the glutaric acid-terminated multi-arm PEO 314 shown reacts in an amide coupling reaction to form an amino-terminated polymer, such as an amino-C1-C4-alkyl-terminated polymer, wherein the amino-C1-C4-alkyl group is attached to the hydrophilic polymer segment via an amide group and a hydrolyzable ester group.

[0061] In some embodiments, the strained alkynyl group can be attached to the carboxylic acid-terminated precursor polymer. Figure 3B In the specific embodiment shown, glutaric acid-terminated multi-arm PEO 314 reacts with a hydroxylated tonicyne (e.g., (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethanol 326) in an ester coupling reaction in the presence of a suitable coupling agent to generate (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl-glutaric acid ester-terminated multi-arm PEO 328, wherein the (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl group is coupled to the polymer arm via two hydrolyzable ester groups. In an alternative embodiment (not shown), an acid-capped multi-arm PEO is reacted with an amine-substituted strained yne (e.g., (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-ylmethylamine) in an amide coupling reaction in the presence of a suitable coupling agent to generate a multi-arm PEO, wherein the (1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl group is coupled to the polymer arm via an amide group and a hydrolyzable ester group.

[0062] In some implementations, the tonicene group can be attached to the carboxylic acid-terminated precursor polymer. Figure 3C In the specific embodiment shown, glutaric acid-terminated multi-arm PEO 314 reacts with a hydroxylated tonicene (e.g., cyclooct-4-en-1-ol 336) in an ester coupling reaction in the presence of a suitable coupling agent to generate cyclooct-4-en-1-yl-glutaric acid-terminated multi-arm PEO 338, wherein the cyclooct-4-en-1-yl group is coupled to the polymer arm via two hydrolyzable ester groups. In an alternative embodiment (not shown), acid-terminated multi-arm PEO reacts with an amine-substituted tonicene (e.g., cyclooct-4-en-1-amine) in an amide coupling reaction in the presence of a suitable coupling agent to generate a multi-arm PEO, wherein the cyclooct-4-en-1-yl group is coupled to the polymer arm via an amide group and a hydrolyzable ester group.

[0063] In some embodiments, the tetraazine group may be attached to the hydroxyl-terminated precursor polymer. Exemplary hydroxyl-terminated precursor polymers are as described above and include... Figure 3A Hydroxyl-terminated precursors include multi-arm polyethylene oxide (PEO) 310, etc. For example, in the presence of a suitable coupling agent, tetrazine-based acids can be coupled to hydroxyl-terminated precursor polymers in ester coupling reactions. Figure 3DIn the specific embodiment shown, the tetrazine-terminated polymer is prepared by coupling the hydroxyl-terminated precursor multi-arm polyethylene oxide (PEO) 310 with 5-[4-(1,2,4,5-tetraazine-3-yl)benzylamino]-5-oxovalerate in the presence of a carbodiimide coupling agent to generate 5-[4-(1,2,4,5-tetraazine-3-yl)benzylamino]-5-oxovalerate ester-terminated multi-arm PEO 338. Note that the reactive tetrazine group is attached to the multi-arm polymer via a hydrolyzable ester group.

[0064] In some embodiments, the azide-terminated polymer can be formed from a hydroxyl-terminated precursor polymer. For example, the azide-terminated polymer can be synthesized by reacting a hydroxyl-terminated precursor multiarm polymer with methanesulfonyl chloride to obtain a methanesulfonyl-terminated multiarm polymer. Sodium azide (NaN3) is then reacted with the methanesulfonyl-terminated multiarm polymer to replace the methanesulfonate group with an azide group, thereby forming the azide-terminated multiarm polymer.

[0065] Exemplary hydroxyl-terminated precursor polymers are as described above, and include... Figure 3A Hydroxyl-terminated precursors include multi-arm polyethylene oxide (PEO) 310, etc.

[0066] In embodiments requiring a hydrolyzable ester-bonded structure and hydroxyl-terminated groups, the hydroxyl-terminated precursor polymer (e.g.) Figure 3A The hydroxyl groups of hydroxyl-terminated precursors (such as poly(ethylene oxide) 310, etc.) can react with lactones (e.g., α-acetyllactone, β-propiolactone, γ-butyrolactone, δ-valerolactone, ε-caprolactone, etc.) in a ring-opening reaction to form hydroxyl-terminated precursor polymers containing hydroxyl end groups. Each hydroxyl position of the hydroxyl-terminated precursor polymer is connected by an alkyl group (e.g., C1-C1) via an alkyl group. 10 Alkyl groups and hydrolyzable ester groups are attached to hydroxyl-terminated residues of the precursor polymer.

[0067] The above strategy is widely applicable to polymers with hydroxyl-terminated segments other than PEO segments (such as the segments disclosed above).

[0068] As previously described, in addition to the reactive polymer comprising the plurality of first hydrophilic polymer segments and the plurality of first reactive moieties as described above, the system described herein also comprises a reactive multifunctional compound containing a plurality of second reactive moieties, wherein the first and second reactive moieties are selected to covalently crosslink with each other to form a crosslinked reaction product.

[0069] In some embodiments, the polyfunctional compound is a compound having two or more nucleophilic groups (e.g., having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more nucleophilic groups). Specific examples of such polyfunctional compounds include, for example, polyamines containing two or more amino groups (-NH2) (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino groups in some embodiments), also referred to herein as polyamine compounds. Polyamine compounds suitable for use in this disclosure include those containing two or more primary amino groups (e.g., -(CH2)). x -NH2 group, where x is 1, 2, 3, 4, 5 or 6) in polyamino compounds. Polyamino compounds suitable for use in this disclosure include those comprising two or more basic amino acid residues, said basic amino acid residues including amino acid residues having two or more primary amine groups, such as lysine and ornithine, for example, polyamines comprising 2 to 10 lysine residues and / or ornithine amino acid residues (e.g., dilysine, trilysine, tetralysine, pentalysine, diornithine, triornithine, tetraornithine, pentaornithine, etc.).

[0070] Other examples of polyamino compounds that can be used as polyfunctional compounds include ethylenediamine, ethylenetriamine, diethylenetriamine, hexamethylenetriamine, di(heptamethyl)triamine, di(trimethylene)triamine, bis(hexamethylene)triamine, tris(2-aminoethyl)amine, tris(3-aminopropyl)amine, 1,3,5-tris-(2-aminoethyl)-[1,3,5]triazine-2,4,6-trione, N,N,N'-tris(2-aminoethyl)ethylenediamine, triethylenetetramine, tripropylenetetramine, N,N',N'-tetra(2-aminoethyl)-1,2-ethylenediamine, tetraethylenepentamine, hexamethyleneheptamine, pentaethylenehexamine, dimethyloctylamine, dimethyldecylamine, and JEFFAMINE polyetheramine (purchased from Huntsman Corporation), as well as poly(allylamine), etc.

[0071] Compounds having at least two amino groups can also be made from polyols as described above. For example, the hydroxyl groups of the polyol can be reacted with the carboxyl groups of a suitable amino acid compound in the presence of a suitable coupling agent in an ester coupling reaction, wherein the amino groups of the amino acid are protected with a suitable protecting group (e.g., a tert-butoxycarbonyl (tBoc) protecting group). Examples of amino acids can be selected from, for example, β-amino acids such as 3-aminopropionic acid (also known as β-alanine), γ-amino acids such as 4-aminobutyric acid (also known as γ-aminobutyric acid or GABA), δ-amino acids such as 5-aminovaleric acid, ε-amino acids such as 6-aminohexanoic acid, etc. Deprotection of the protecting group yields a compound in which a primary amino group is attached to a residue of the polyol at each hydroxyl position via a hydrolyzable ester group.

[0072] In some embodiments, the multifunctional compound is a compound having two or more electrophilic groups (e.g., having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more electrophilic groups). The electrophilic groups may be selected from, for example, cyclic imide ester groups (e.g., succinimide ester groups, maleimide ester groups, glutarimide ester groups, diethylene glycol imide ester groups, phthalimide ester groups, and bicyclic [2.2.1]hept-5-ene-2,3-dicarboxylic acid imide ester groups), imidazole ester groups, imidazole carboxylic acid ester groups, and benzotriazole ester groups, etc.

[0073] Commercially available compounds containing at least two cyclic imide ester groups include disuccinimide glutarate (containing two cyclic imide esters), 1,5-bis(2,5-dioxo-1-pyrrolidinyl)2-oxoglutarate (containing two cyclic imide esters), 1,5-bis(2,5-dioxo-1-pyrrolidinyl)3-hydroxyglutarate (containing two cyclic imide esters), and 1,2,3-tris(2,5-dioxo-1-pyrrolidinyl)2-hydroxy-1,2,3-propanetricarboxylic acid ester (containing three cyclic imide esters).

[0074] Compounds containing at least two cyclic imide ester groups can also be derived from compounds having at least two carboxylic acid groups according to the following combination. Figure 3A The described route involves the reaction of an N-hydroxycyclic imide compound (such as one of those described above) with a coupling agent to form the compound. Compounds having at least two carboxylic acid groups also include a variety of known polycarboxylic acid compounds, such as glutaric acid, succinic acid, malonic acid, adipic acid, diethylene glycol, citric acid, isocitrate, trimellitic acid, pyromellitic acid, aconitic acid, propane-1,2,3-tricarboxylic acid (propanetricarboxylic acid), ethanetricarboxylic acid, butane-1,2,3,4-tetracarboxylic acid, and ethane-1,1,2,2-tetracarboxylic acid. In one specific example, the polycarboxylic acid compound reacts with an N-hydroxysuccinimide to form a succinimide ester group at the position previously occupied by the carboxylic acid group of the polycarboxylic acid compound.

[0075] Compounds having at least two carboxylic acid groups can also be made from polyols as described above. For example, a polyol can react with the aforementioned cyclic anhydride compound in a ring-opening reaction to form a polycarboxylic acid compound, wherein each carboxylic acid group is linked to a residue of the polyol via a hydrolyzable ester group. The polycarboxylic acid compound can then react with an N-hydroxycyclic imide compound (such as one of those described above) in the presence of a coupling agent to form a compound wherein the cyclic imide ester group is linked to a polyol residue via an ester bond structure.

[0076] In some embodiments, the polyfunctional compound is a compound having at least two strained alkynyl groups (e.g., having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more strained alkynyl groups). The strained alkynyl groups may be selected from, for example, (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl and dibenzocyclooctynyl, as well as other possible groups.

[0077] Commercially available compounds containing at least two strained alkynyl groups include 5,8-dioxa-2,11-diazadodecanoic acid 1,12-bis[(1R,8S)-bicyclo[6.1.0]non-4-yn-9-ylmethyl] ester, poly(oxy-1,2-ethylenedimethyl) (CAS1476737-97-9), α-[2-[[[(1α,8α,9β)-bicyclo[6.1.0]non-4-yn-9-ylmethoxy]carbonyl]amino]ethyl]-ω-[2-[[[(1α,8α,9β)-bicyclo[6.1.0]non-4-yn-9-ylmethoxy]carbonyl]amino]ethoxy] (CAS2152700-22-4), 2-(9-bicyclo[6.1.0]non-4-ynylmethoxy)-~{N}-[5-[[2-(9-bicyclo[6.1.0]non-4-ynylmethoxy)acetyl]amino]pentyl]acetamide (CAS 2743204-05-7), 2-(9-bicyclo[6.1.0]non-4-ynylmethoxy)-~{N}-[2-[2-[[2-(9-bicyclo[6.1.0]non-4-ynylmethoxy)acetyl]amino]ethoxy]ethyl]acetamide (CAS 2752158-76-0).

[0078] Compounds containing at least two strained alkynyl groups can also be formed from polycarboxylic acid compounds containing at least two carboxylic acid groups.

[0079] Polycarboxylic acid compounds containing at least two carboxylic acid groups include a variety of known polycarboxylic acid compounds, such as glutaric acid, succinic acid, malonic acid, adipic acid, diethylene glycol, citric acid, isocitric acid, trimellitic acid, pyromellitic acid, aconitic acid, propane-1,2,3-tricarboxylic acid (propanetricarboxylic acid), ethanetricarboxylic acid, butane-1,2,3,4-tetracarboxylic acid, and ethane-1,1,2,2-tetracarboxylic acid. Polycarboxylic acid compounds containing at least two carboxylic acid groups can also be prepared from polyols as described above.

[0080] For example, the carboxylic acid group of a polycarboxylic acid compound can react with a hydroxyl-substituted anthrylene (e.g., (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-ylmethanol) in an ester coupling reaction in the presence of a suitable coupling agent to generate (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl, which is coupled to the residues of the polycarboxylic acid compound via two hydrolyzable ester groups. In an alternative embodiment, the carboxyl group of the polycarboxylic acid compound can react with an amine-substituted anthrylene (e.g., (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-ylmethylamine) in an amide coupling reaction in the presence of a suitable coupling agent to generate a compound wherein the (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl is linked to the residues of the polycarboxylic acid compound via an amide group and a hydrolyzable ester group.

[0081] In some embodiments, the polyfunctional compound is a compound having at least two tonicenyl groups (e.g., having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more tonicenyl groups). The tonicenyl group may be selected from, for example, cyclooctyl-4-en-1-yl, cyclooctyl-4-enyl 2,5-dioxopyrrolidine-1-yl carbonate, N-(3-aminopropyl)-4-cycloocten-1-yl ester of carbamate, and N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-4-cycloocten-1-yl ester of carbamate, and other possible groups.

[0082] Commercially available compounds containing at least two tonicenyl groups include 5,8,11,14,17,20,23,26-octaoxa-2,29-diazatriacontanedioic acid, 1,30-di-4-cyclooctene-1-yl ester, and 5,8,11,14- Tetraoxa-2,17-diazaoctadecanoic acid, 1,18-di-4-cyclooctene-1-yl ester, cyclooctene, 5,5'-[1,2-ethylenedimethylbis(oxy-2,1-ethylenedioxy)]bis-, and cyclooctene, 5,5',5”-[(methylsilyl)tris(oxy)]tris- (5,5′,5′′-[(methylsilylidyne)tris(oxy)]tris-).

[0083] Compounds containing at least two toninyl groups can also be formed from polycarboxylic acid compounds containing at least two carboxylic acid groups. For example, the carboxylic acid group of the polycarboxylic acid compound can react with a hydroxyl-substituted toninene (e.g., cyclooct-4-en-1-ol) in the presence of a suitable coupling agent in an ester coupling reaction to generate a compound in which the cyclooct-4-en-1-yl group is linked to the residues of the polycarboxylic acid compound via two hydrolyzable ester groups. In an alternative embodiment, the carboxyl group of the polycarboxylic acid compound can react with an amine-substituted toninene (e.g., cyclooct-4-en-1-amine) in the presence of a suitable coupling agent in an amide coupling reaction to generate a compound in which the cyclooct-4-en-1-yl group is linked to the residues of the polycarboxylic acid compound via an amide group and a hydrolyzable ester group.

[0084] Polycarboxylic acid compounds containing at least two carboxylic acid groups include a variety of known polycarboxylic acid compounds, such as those mentioned above. Polycarboxylic acid compounds containing at least two carboxylic acid groups can also be made from polyols as described above.

[0085] In some embodiments, the multifunctional compound is a compound having at least two tetrazine groups (e.g., having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more tetrazine groups).

[0086] Commercially available compounds containing at least two tetrazine groups include 5,5'-bi-1,2,3,4-tetrazine.

[0087] Compounds containing at least two tetrazine groups can also be formed from polyols containing at least two hydroxyl groups. Exemplary polyols include those described above for forming multi-arm polymers.

[0088] In some embodiments, in the presence of a suitable coupling agent, a tetrazine-based acid can be coupled to the hydroxyl group of a polyol containing at least two hydroxyl groups in an ester coupling reaction. In one specific example, a polyfunctional compound containing a tetrazine group can be prepared by coupling a hydroxyl group of a polyol with 5-[4-(1,2,4,tetraazine-3-yl)benzylamino]-5-oxovalerate acid in the presence of a carbodiimide coupling agent to generate a compound wherein a 5-[4-(1,2,4,5-tetraazine-3-yl)benzylamino]-5-oxovalerate ester group is attached to a polyol residue at each hydroxyl position of the precursor polyol. Note that each 5-[4-(1,2,4,5-tetraazine-3-yl)benzylamino]-5-oxovalerate ester group contains a hydrolyzable ester group.

[0089] In some embodiments, the multifunctional compound is a compound having at least two azide groups (e.g., having 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more azide groups).

[0090] Commercially available compounds containing at least two azido groups include 1,1'-oxybis[2-(2-azidoethoxy)ethane], 1,17-diazido-3,6,9,12,15-pentaheptadecane, N,N'-(dithiodi-2,1-ethylenediyl)bis[4-azido-2-hydroxybenzamide], 1-azido-3-[(2-azidoethoxy)methoxy]propane (1-azido-3-[(2-azidoethoxy)methoxy]-), and 1,3,5-tris(azidomethyl)-2,4,6-triethylbenzene.

[0091] Polyfunctional compounds having at least two azide groups can be formed from polyols having at least two hydroxyl groups. Exemplary polyols include those described above for forming multi-arm polymers.

[0092] For example, a polyfunctional compound having at least two azido groups can be synthesized by reacting the hydroxyl groups of a polyol with methanesulfonyl chloride to obtain a polyfunctional compound having at least two methanesulfonyl groups. Then, sodium azide (NaN3) is reacted with the polyfunctional compound having at least two methanesulfonyl groups to replace the methanesulfonyl groups with azido groups, thereby forming a polyfunctional compound having at least two azido groups.

[0093] Polyols having at least two hydroxyl groups and biodegradable ester groups can also be made from the polyols described above for forming multi-arm polymers. For example, the precursor polyol can react with lactones (e.g., α-acetyllactone, β-propiolactone, γ-butyrolactone, δ-valerolactone, ε-caprolactone, etc.) in a ring-opening reaction to form another polyol containing a hydroxyl end group, which is located at each hydroxyl position of the polyol via an alkyl group (e.g., C1-C1). 10 An alkyl group and a hydrolyzable ester group are attached to residues of a precursor polyol. This polyol can be used to form a multifunctional compound having at least two azido groups, as described above. The at least two azido groups will then be attached to the remainder of the multifunctional compound.

[0094] As previously described, in addition to reactive polymers comprising multiple first hydrophilic polymer segments and multiple first reactive moieties, and reactive multifunctional compounds comprising multiple second reactive moieties, the systems described herein also comprise gold nanoparticles functionalized with multiple second hydrophilic polymer segments. The first and second hydrophilic polymer segments may be formed from the same monomer or different monomers.

[0095] Gold nanoparticles can be solid gold particles, or they can include a gold shell surrounding a core particle formed of a metal other than gold (e.g., tantalum or tungsten). The gold in the nanoparticles can be substantially pure gold or can be a gold alloy (e.g., gold alloyed with one or more metals selected from silver, platinum, copper, titanium, rhodium, palladium, zinc, nickel, iron, and aluminum).

[0096] Gold nanoparticles can be supplied in a variety of shapes, including spherical, rod-shaped, plate-shaped, and irregular shapes. The size of the gold nanoparticles can be selected according to the specific imaging application and the required X-ray impermeability. See Xi, D. et al., Gold nanoparticles as computerized tomography (CT) contrast agents. RSC Adv. 2012, 2 (33), 12515-12524. For example, in the case of X-ray-based imaging, the longest dimension of the particles (e.g., the diameter of a sphere, the length of a rod, the maximum width of a plate, etc.) can be in the range of 1 nm to 2000 nm, for example, any value in the range of 1 nm to 2 nm to 5 nm to 10 nm to 20 nm to 50 nm to 100 nm to 200 nm to 500 nm to 1000 nm to 2000 nm. As another example, when imaging is based on near-IR fluorescence spectroscopy, the longest particle size can be in the range of 20 nm to 500 nm, for example, any value in the range of 20 nm to 50 nm to 100 nm to 200 nm to 500 nm.

[0097] Now refer to Figure 2 The illustration shows a functionalized gold nanoparticle 216 according to the present disclosure, which comprises a plurality of polymer chains connected to gold nanoparticles 212, the polymer chains comprising hydrophilic polymer segments 214. One end of the hydrophilic polymer segments 214 is covalently connected to the gold nanoparticles 212.

[0098] Gold nanoparticles can be surface-functionalized with hydrophilic polymers comprising hydrophilic polymer segments 214 containing a thiol group (-SH group) at one end. Surface functionalization of gold nanoparticles readily occurs when the thiol-terminated polymer is added to a solution of gold nanoparticles. See, e.g., Gao, J. et al., Colloidal Stability of Gold Nanoparticles Modified with Thiol Compounds: Bioconjugation and Application in Cancer Cell Imaging. Langmuir 2012, 28 (9), 4464-4471; Zopes, D. et al., Improved Stability of “Naked” Gold Nanoparticles Enabled by in SituCoating with Mono and Multivalent Thiol PEG Ligands. Langmuir 2013, 29 (36), 11217-11226; Hinterwirth, H. et al., Quantifying Thiol Ligand Density of Self-Assembled Monolayers on Gold Nanoparticles by Inductively Coupled Plasma–MassSpectrometry. ACS Nano 2013, 7 (2), 1129-1136.

[0099] In some embodiments, after surface functionalization by reacting with a thiol-terminated hydrophilic polymer comprising hydrophilic polymer segments and thiol groups, the functionalized gold nanoparticles can be surface passivated to prevent further reaction of the gold surface with reactive multifunctional compounds, such as those described herein. For example, the gold surface can be passivated with a citrate ligand. The citrate ligand will be replaced by the thiol-terminated hydrophilic polymer; however, some citrate ligands may be retained. The ratio of the thiol-terminated hydrophilic polymer to the citrate ligand (or other ligands) can be varied to optimize the method.

[0100] The hydrophilic polymer segments used to form functionalized gold nanoparticles can be selected from any of a variety of synthetic, natural, or synthetic-natural hybrid hydrophilic polymer segments. Examples of hydrophilic polymer segments include those formed from one or more hydrophilic monomers selected from: C1-C6-epoxides (e.g., ethylene oxide, propylene oxide, tetramethylene oxide, etc.), polar aprotic vinyl monomers (e.g., N-vinylpyrrolidone, acrylamide, N-methacrylamide, dimethacrylamide, N-vinylimidazolium, 4-vinylimidazolium, sodium 4-vinylbenzenesulfonate, etc.), dioxanehexanone, ester monomers (e.g., glycolide, lactide, β-propiolactone, β-butyrolactone, γ-butyrolactone, γ-pentylenesulfonate, etc.). lactones, δ-valerolactone, ε-caprolactone, etc.), oxazoline monomers (e.g., oxazoline and 2-alkyl-2-oxazoline, such as 2-(C1-C6 alkyl)-2-oxazoline, including various isomers such as 2-methyl-2-oxazoline, 2-ethyl-2-oxazoline, 2-n-propyl-2-oxazoline, 2-isopropyl-2-oxazoline, 2-n-butyl-2-oxazoline, 2-isobutyl-2-oxazoline, 2-hexyl-2-oxazoline, etc.), 2-phenyl-2-oxazoline, N-isopropylacrylamide, amino acids and sugars.

[0101] The hydrophilic polymer segments can be selected from, for example, the following polymer segments: polyether segments, including poly(epoxyalkylene) segments, such as poly(ethylene oxide) (PEO) (also known as polyethylene glycol or PEG) segments, poly(propylene oxide) segments, and poly(ethylene oxide-co-propylene oxide) segments; polymer segments formed from one or more polar aprotic vinyl monomers, including poly(N-vinylpyrrolidone) segments, poly(acrylamide) segments, poly(N-methacrylamide) segments, poly(dimethacrylamide) segments, poly(N-vinylimidazolium) segments, poly(4-vinylimidazolium) segments, and poly(sodium 4-vinylbenzenesulfonate) segments; polydioxane segments; polyester segments, including polyglycolic acid segments, polylactic acid segments, poly(lactic acid-co-glycolic acid) segments, and poly(β-propanediol) segments. The segments include: lactone segments, poly(β-butyrolactone) segments, poly(γ-butyrolactone) segments, poly(γ-valerolactone) segments, poly(δ-valerolactone) segments, and poly(ε-caprolactone) segments; polyoxazoline segments, including poly(2-C1-C6-alkyl-2-oxazoline) segments, such as poly(2-methyl-2-oxazoline) segments, poly(2-ethyl-2-oxazoline) segments, poly(2-propyl-2-oxazoline) segments, poly(2-isopropyl-2-oxazoline) segments, poly(2-n-butyl-2-oxazoline) segments, poly(2-phenyl-2-oxazoline) segments, poly(N-isopropylacrylamide) segments, polypeptide segments, or polysaccharide segments. Polysaccharide segments include those containing one or more uronic acid substances, such as galacturonic acid, glucuronic acid, and / or iduronic acid. Specific examples of polysaccharide segments include alginic acid, hyaluronic acid, pectin, agar, carrageenan, gellan gum, gum arabic, guar gum, xanthan gum, and carboxymethyl cellulose fractions.

[0102] The polymer segments used in the functionalized gold nanoparticles of this disclosure typically contain 5 or fewer to 100 or more monomer units, or more, for example, in the range of 2 to 5 to 10 to 20 to 50 to 100 to 200 monomer units in length.

[0103] In various embodiments, the polymer segments of the functionalized gold nanoparticles of this disclosure are formed from the same monomers as the polymer segments of the reactive polymers.

[0104] As previously described, in some aspects, this disclosure provides a radiopaque hydrogel comprising (a) a crosslinked reaction product of a reactive polymer as described herein and (b) a reactive multifunctional compound as described herein. In various embodiments, the reactive polymer will have three or more first reactive end groups (e.g., three or more polymer arms capped with a first reactive portion R1), and the multifunctional compound will have two or more second reactive end groups.

[0105] Figures 4A-4CThree specific examples of covalent crosslinking reactions between the first reactive portion and the second reactive portion are shown.

[0106] Figure 4A A covalent crosslinking reaction between a cyclic amide ester group (specifically a succinimide ester group 410) and a primary amine group 412 is shown, thereby forming an amide linking group 414. In this embodiment, the first reactive portion may contain a cyclic amide ester group and the second reactive portion may contain a primary amine group, or the first reactive portion may contain a primary amine group and the second reactive portion may contain a cyclic amide ester group.

[0107] Figure 4B The formation of cycloocttriazole covalently bonded structure 424 is shown by a strain-promoted azido-yne cycloaddition click chemistry (SPACC) reaction between a strained alkynyl group (specifically (1R,8S,9S)-bicyclo[6.1.0]non-4-yn-9-yl-ester 420) and an azide group 422. Figure 4B The boxes in the diagram indicate the locations where new covalent bonds are formed. In this scheme, the first reactive portion may contain a strained alkynyl group, and the second reactive portion may contain an azide group, or the first reactive portion may contain an azide group, and the second reactive portion may contain a strained alkynyl group.

[0108] Figure 4C The formation of a cyclooctazine covalently bonded structure 434 via a strain-promoted tetrazine linkage coupling reaction between a tetrazine group (specifically 1,2,4,5-tetrazine-3-yl 430) and a torin group (specifically cyclooct-4-en-1-yl-ester group 432) is illustrated. Figure 4C The boxes in the diagram indicate the positions where new covalent bonds are formed. In this scheme, the first reactive portion may contain a torinyl group and the second reactive portion may contain a tetrazinyl group, or the first reactive portion may contain a tetrazinyl group and the second reactive portion may contain a torinyl group.

[0109] Overall cross-linking reaction such as Figure 5 As illustrated schematically, it shows that in the presence of functionalized gold nanoparticles 518, a reactive multi-arm polymer 510 having multiple first reactive moieties (represented by circles 510r) and a reactive multifunctional compound 516 having multiple reactive moieties (represented by circles 515r) are covalently cross-linked to form a cross-linking reaction product (specifically, a cross-linked radiopaque hydrogel 520), wherein covalent bonds (represented by circles 520c) are formed between the reactive multi-arm polymer 510 and the reactive multifunctional compound 516.

[0110] In various embodiments, prior to hydrogel formation, functionalized gold nanoparticles are uniformly mixed with reactive multi-arm polymers and / or reactive multifunctional compounds. After hydrogel formation, the functionalized gold nanoparticles are locked into the hydrogel through non-covalent interactions (e.g., chain entanglement and / or hydrophilic interactions such as hydrogen bonds) between hydrophilic polymer segments in the hydrophilic polymer chains attached to the surface of the functionalized gold nanoparticles and hydrophilic polymer segments in the polymer arms of the multi-arm polymer covalently bound to the hydrogel.

[0111] For example, the radiation impermeability of the hydrogel can be tuned by varying the concentration of functionalized gold nanoparticles in the hydrogel. In some embodiments, the concentration of functionalized gold nanoparticles in the hydrogel is in the range of 0.01 mg / mL or less to 100 mg / mL or greater, for example, any value in the range of 0.01 mg / mL to 0.02 mg / mL to 0.05 mg / mL to 0.1 mg / mL to 0.2 mg / mL to 0.5 mg / mL to 1 mg / mL to 2 mg / mL to 5 mg / mL to 10 mg / mL.

[0112] In some embodiments, this disclosure provides a hydrogel comprising functionalized gold nanoparticles and a crosslinking reaction product of a reactive polymer and a multifunctional compound, wherein the reactive polymer comprises a first reactive portion containing an electrophilic group, and the multifunctional compound comprises a second reactive portion containing a nucleophilic group. In some embodiments, this disclosure provides a hydrogel comprising functionalized gold nanoparticles and a crosslinking reaction product of a reactive polymer and a multifunctional compound, wherein the reactive polymer comprises a first reactive portion containing a nucleophilic group, and the multifunctional compound comprises a second reactive portion containing an electrophilic group.

[0113] In some embodiments, this disclosure provides a system for forming a hydrogel by mixing the following substances in a reaction mixture: functionalized gold nanoparticles, a reactive polymer comprising a first reactive portion containing an electrophilic group, and a multifunctional compound comprising a second reactive portion containing a nucleophilic group. The functionalized gold nanoparticles, the reactive polymer, and the multifunctional compound are mixed under conditions that crosslink the electrophilic and nucleophilic groups to form a hydrogel and trap the functionalized gold nanoparticles within the hydrogel. In some embodiments, those conditions include an environment with an alkaline pH (e.g., pH in the range of about 9 to about 11). Such hydrogels can be formed in vivo or in vitro.

[0114] In some embodiments, this disclosure provides a hydrogel comprising functionalized gold nanoparticles and a crosslinking reaction product of a reactive polymer and a multifunctional compound, wherein the reactive polymer comprises a first reactive moiety containing a strained alkynyl group, and the multifunctional compound comprises a second reactive moiety containing an azide group.

[0115] In some embodiments, this disclosure provides a system for forming a hydrogel by mixing the following substances in a reaction mixture: functionalized gold nanoparticles, a reactive polymer comprising a first reactive portion containing an azido group, and a multifunctional compound comprising a second reactive portion containing an azido group. The reactive polymer and the multifunctional compound are mixed under conditions that crosslink the azido and azido groups to form a hydrogel and trap the functionalized gold nanoparticles within the hydrogel. Such a hydrogel can be formed in vivo or in vitro.

[0116] In some embodiments, this disclosure provides a hydrogel comprising functionalized gold nanoparticles and a crosslinking reaction product of a reactive polymer and a multifunctional compound, wherein the reactive polymer comprises a first reactive moiety containing a torazine group, and the multifunctional compound comprises a second reactive moiety containing a tetrazine group.

[0117] In some embodiments, this disclosure provides a system for forming a hydrogel comprising a crosslinked reaction product by mixing the following substances in a reaction mixture: functionalized gold nanoparticles, a reactive polymer comprising a first reactive portion containing a torinyl group, and a multifunctional compound comprising a second reactive portion containing a tetrazine group. The reactive polymer and the multifunctional compound are mixed under conditions that crosslink the torinyl group and the tetrazine group to form a hydrogel and trap the functionalized gold nanoparticles within the hydrogel. Such a hydrogel can be formed in vivo or in vitro.

[0118] In various embodiments, the hydrogel of this disclosure is visible under fluorescence fluoroscopy. In various embodiments, for example, when measured on a desktop miniature CT system (e.g., Scanco Medical's XtremeCT or similar system in Wangen-brüttisellen, Switzerland), the radiopaqueness of such crosslinked products is greater than 100 Hounsfield units (HU), advantageously any value in the range of 100 HU to 250 HU to 500 HU to 750 HU to 1000 HU to 2000 HU or higher (in other words, within the range of any two of the aforementioned values).

[0119] The hydrogel disclosed herein can be used in a variety of biomedical applications, including implants, medical devices, and pharmaceutical compositions.

[0120] In some aspects of this disclosure, a system is provided comprising: (a) a first composition comprising a reactive polymer as described herein, and (b) a second composition comprising a multifunctional compound as described herein, wherein the first composition, the second composition, or both comprise functionalized gold nanoparticles as described herein, and wherein when the first composition and the second composition are mixed, covalent cross-links are formed between the reactive polymer and the multifunctional compound to generate a hydrogel and trap the functionalized gold nanoparticles within the hydrogel.

[0121] The first composition may be a first fluid composition containing a multifunctional compound or a first dry composition containing a multifunctional compound. A suitable fluid (e.g., water for injection, saline, etc.) may be added to the first dry composition to form the first fluid composition. In addition to the multifunctional compound, the first composition may also contain functionalized gold nanoparticles and / or other reagents (including therapeutic agents, imaging agents, colorants, tension modifiers, suspending agents, wetting agents, and pH adjusters as described below).

[0122] The second composition may be a second fluid composition containing a reactive polymer or a second dry composition containing a reactive polymer. A suitable fluid (e.g., water for injection, saline, etc.) may be added to the second dry composition to form the second fluid composition. In addition to the reactive polymer, the second composition may also contain functionalized gold nanoparticles and / or other reagents (including therapeutic agents, imaging agents, colorants, tension modifiers, suspending agents, wetting agents, and pH adjusters as described below).

[0123] In some embodiments, the system is configured to mix a first fluid composition comprising a multifunctional compound with a second fluid comprising a reactive polymer, wherein the first composition, the second composition, or both comprise functionalized gold nanoparticles as described herein, and wherein the first composition, the second composition, or both may optionally comprise additional reagents as described herein. Upon mixing the first and second fluid compositions, the multifunctional compound crosslinks with the reactive polymer to form a hydrogel, trapping the functionalized gold nanoparticles within the hydrogel. The first and second fluid compositions can be mixed in vivo or in vitro to form a radiopaque crosslinked hydrogel.

[0124] In some embodiments, the multifunctional compound is initially mixed with the reactive polymer under conditions where crosslinking between the reactive polymer and the multifunctional compound is inhibited (e.g., in some embodiments, an acidic pH). Then, when crosslinking is required, the conditions are changed to increase crosslinking (e.g., in some embodiments, from an acidic pH to an alkaline pH), resulting in crosslinking between the multifunctional compound and the reactive polymer, thereby forming a crosslinked product.

[0125] In some embodiments, the system comprises (a) a first composition comprising a multifunctional compound as described herein and a reactive polymer as described herein, and (b) a second composition (specifically an accelerator composition) containing an accelerator configured to accelerate a crosslinking reaction between the multifunctional compound and the reactive polymer. In some embodiments, the first composition may also comprise functionalized gold nanoparticles as described herein and / or additional reagents. In some embodiments, the second composition may also comprise functionalized gold nanoparticles as described herein and / or additional reagents. In some embodiments, the system may comprise a third composition comprising functionalized gold nanoparticles as described herein.

[0126] In some embodiments, the system comprises (a) a first composition comprising a multifunctional compound as described herein, (b) a second composition comprising a reactive polymer as described herein, and (c) a third composition (specifically an accelerator composition) containing an accelerator configured to accelerate a crosslinking reaction between the multifunctional compound and the reactive polymer. In some embodiments, the first composition may also comprise functionalized gold nanoparticles as described herein and / or additional reagents. In some embodiments, the second composition may also comprise functionalized gold nanoparticles as described herein and / or additional reagents. In some embodiments, the third composition may also comprise functionalized gold nanoparticles as described herein and / or additional reagents. In some embodiments, the system may comprise a fourth composition comprising functionalized gold nanoparticles as described herein.

[0127] The first composition may be a first fluid composition containing a multifunctional compound buffered to an acidic pH or a first dry composition containing a multifunctional compound. A suitable fluid (e.g., water for injection, saline, acid buffer solution, etc.) may be added to the first dry composition to form a first fluid composition containing a multifunctional compound buffered to an acidic pH. For example, in some embodiments, the acid buffer composition may include sodium dihydrogen phosphate, etc. The first fluid composition containing the multifunctional compound may have a pH in the range of, for example, from about 3 to about 5. In addition to the multifunctional compound, the first composition may also contain functionalized gold nanoparticles and / or other agents (including therapeutic agents, imaging agents, colorants, tension modifiers, suspending agents, wetting agents, and pH adjusters as described below).

[0128] The second composition may be a second fluid composition comprising a reactive polymer or a second dry composition comprising a reactive polymer, wherein the fluid composition is formed from the second dry composition, for example by adding a suitable fluid (e.g., water for injection, saline, or a first fluid composition comprising a multifunctional compound buffered to an acidic pH). In addition to the reactive polymer, the second composition may also comprise functionalized gold nanoparticles and / or other reagents (including therapeutic agents, imaging agents, colorants, tension modifiers, suspending agents, wetting agents, and pH adjusters as described below).

[0129] In a specific embodiment, the first composition is a first fluid composition containing a multifunctional compound (and in some cases, functionalized gold nanoparticles and / or other reagents) buffered to an acidic pH, and the second composition is a dry composition containing a reactive polymer (and in some cases, functionalized gold nanoparticles and / or other reagents). The first composition and the second composition can then be mixed to provide a prepared fluid composition buffered to an acidic pH and containing the multifunctional compound and the reactive polymer. In one specific example, a syringe containing the first fluid composition containing the multifunctional compound buffered to an acidic pH can be provided, and a vial containing the dry composition (e.g., powder) containing the reactive polymer can also be provided. The first fluid composition can then be injected into the vial containing the reactive polymer using the syringe to form the prepared fluid composition buffered to an acidic pH and containing the multifunctional compound and the reactive polymer, which can then be aspirated back into the syringe for administration.

[0130] The accelerator composition can be a liquid accelerator composition buffered to an alkaline pH, or a dry composition containing an alkaline buffer composition. A suitable fluid (e.g., water for injection, saline, etc.) can be added to the dry composition to form a fluid accelerator composition buffered to an alkaline pH. For example, the alkaline buffer composition may include sodium borate and disodium hydrogen phosphate, etc. The fluid accelerator composition may have a pH in the range of, for example, from about 9 to about 11. In addition to the above, the fluid accelerator composition may also contain functionalized gold nanoparticles and / or other reagents, including those described below.

[0131] A prepared fluid composition buffered to an acidic pH and comprising the multifunctional compounds and reactive polymers as described above (and in some cases, functionalized gold nanoparticles and / or other reagents), and a fluid accelerator composition buffered to an alkaline pH as described above (which may in some cases comprise functionalized gold nanoparticles and / or other reagents), can be mixed in vivo or in vitro to form a radiopaque crosslinked hydrogel.

[0132] Other agents used in the compositions described herein include therapeutic agents, imaging agents, colorants, tension modifiers, suspending agents, wetting agents, and pH adjusters.

[0133] Examples of therapeutic agents include antithrombotic agents, anticoagulants, antiplatelet agents, thrombolytic agents, antiproliferative agents, anti-inflammatory agents, proliferative inhibitors, anti-restenosis agents, smooth muscle cell inhibitors, antibiotics, antimicrobial agents, analgesics, anesthetics, growth factors, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters, anti-angiogenic agents, cytotoxic agents, chemotherapeutic agents, checkpoint inhibitors, immunomodulatory cytokines, T-cell agonists, STING (interferon gene stimulator) agonists, antimetabolites, alkylating agents, microtubule inhibitors, hormones, hormone antagonists, monoclonal antibodies, antimitotic agents, immunosuppressants, tyrosine and serine / threonine kinases, proteasome inhibitors, matrix metalloproteinase inhibitors, Bcl-2 inhibitors, DNA alkylating agents, spindle poisons, poly(DP-ribose) polymerase (PARP) inhibitors, and combinations thereof.

[0134] Examples of imaging agents include (a) fluorescent dyes, such as fluorescein, indocyanine green, or fluorescent proteins (e.g., green, blue, and blue-green fluorescent proteins); (b) contrast agents used in conjunction with magnetic resonance imaging (MRI), including contrast agents containing elements that form paramagnetic ions (e.g., Gd(III), Mn(II), Fe(III)) and compounds containing these elements (including chelates) (e.g., gadolinium ions chelated with diethylenetriaminepentaacetic acid); (c) contrast agents used in conjunction with ultrasound imaging, including organic and inorganic echogenic particles (i.e., particles that result in increased reflected ultrasound energy) or organic and inorganic echolucent particles (i.e., particles that result in decreased reflected ultrasound energy); and (d) contrast agents used in conjunction with near-infrared (NIR) imaging, which may be selectively used to impart near-infrared fluorescence to the hydrogels of this disclosure, thereby allowing for deep tissue imaging and device labeling, such as NIR-sensitive nanoparticles (in addition to functionalized gold particles), such as carbon nanotubes (e.g., nanotubes derived with hydroxyl or carboxyl groups). Examples include partially oxidized carbon nanotubes, dye-containing nanoparticles (e.g., dye-doped nanofibers and dye-encapsulated nanoparticles), and semiconductor quantum dots, as well as NIR-sensitive dyes (e.g., cyanine dyes, squaranes, phthalocyanines, porphyrin derivatives, and borodipyrrolizidine analogues), (e) imageable radioactive isotopes, including 99mTc, 201Th, 51Cr, 67Ga, 68Ga, 111In, 64Cu, 89Zr, 59Fe, 42K, 82Rb, 24Na, 45Ti, 44Sc, 51Cr, and 177Lu, and (f) radioactive contrast agents (other than functionalized gold particles), such as particles of tantalum, tungsten, rhenium, niobium, molybdenum, and their alloys, which may be spherical or non-spherical. Other examples of contrast agents include nonionic contrast agents such as iohexol, iodixanol, iofluoxetine, iopamidol, ioxilan, or iopromide; ionic contrast agents such as diatrizoate, iothalamate, metrizoate, or ioxaglate; and iodized oils, including ethiodized poppyseed oil (available as Lipiodol®).

[0135] Examples of colorants include brilliant blue (e.g., brilliant blue FCF, also known as FD&C blue 1), indigocarmine (also known as FD&C blue 2), indigocarmine lake, FD&C blue 1 lake, and methylene blue (also known as methylene blue chloride), etc.

[0136] Other examples of reagents include tension modifiers such as sugars (e.g., glucose, lactose, etc.), polyols (e.g., glycerol, propylene glycol, mannitol, sorbitol, etc.) and inorganic salts (e.g., potassium chloride, sodium chloride, etc.), suspending agents including various surfactants, wetting agents and polymers (e.g., albumin, PEO, polyvinyl alcohol, block polymers, etc.), and pH adjusters including various buffer solutes.

[0137] In various embodiments, a system is provided that includes one or more delivery devices for delivering a first composition and a second composition to a subject.

[0138] In some embodiments, the system may include a delivery device comprising a first reservoir and a second reservoir, the first reservoir containing a first fluid composition comprising the multifunctional compound as described above, and the second reservoir containing a second fluid composition comprising the reactive polymer as described above, wherein the first fluid composition and the second fluid composition, upon mixing, form a crosslinked product. As previously stated, the first fluid composition, the second fluid composition, or both contain functionalized gold nanoparticles as described herein. Furthermore, the first fluid composition, the second fluid composition, or both may optionally contain additional reagents as described herein.

[0139] In some embodiments, the system may include a delivery device comprising a first reservoir and a second reservoir. The first reservoir contains a first fluid composition comprising a multifunctional compound and a reactive polymer and buffered to an acidic pH, such as the aforementioned preparative fluid composition. The second reservoir contains a second fluid composition, such as the aforementioned fluid accelerator composition. As previously stated, the first fluid composition, the second fluid composition, or both may contain functionalized gold nanoparticles as described herein. Furthermore, the first fluid composition, the second fluid composition, or both may optionally contain additional reagents as described herein.

[0140] In either case, during operation, the first fluid composition and the second fluid composition are dispensed from the first reservoir and the second reservoir and mixed, thereby crosslinking the multifunctional compound and the reactive polymer with each other to form a radiopaque crosslinked hydrogel.

[0141] In the specific implementation plan, and referring to Figure 6The system may include a delivery device 610 comprising a dual-tube syringe, the dual-tube syringe including a first tube 612a having a first tube outlet 614a (the first tube contains a first composition and a first plunger 616a movable within the first tube 612a), and a second tube 612b having a second tube outlet 614b (the second tube 612b contains a second composition and a second plunger 616b movable within the second tube 612b). In some embodiments, the device 610 may further include a mixing section 618 having a first mixing section inlet 618a1 in fluid communication with the first tube outlet 614a, a second mixing section inlet 618b1 in fluid communication with the second tube outlet, and a mixing section outlet 618o.

[0142] In some embodiments, the delivery device may further include a needle or conduit configured to receive a first fluid composition and a second fluid composition from a first tube and a second tube. For example, the needle or conduit may be configured to form a fluid connection with the outlet of the mixing section by attaching the needle or conduit to the outlet of the mixing section (e.g., via a suitable fluid connector such as a Luer connector).

[0143] As another example, the catheter may be a multi-lumen catheter including a first lumen and a second lumen, the proximal end of the first lumen being configured to form a fluid connection with a first tube outlet, and the proximal end of the second lumen being configured to form a fluid connection with a second tube outlet. In some embodiments, the multi-lumen catheter may include a mixing portion having a first mixing portion inlet in fluid communication with the distal end of the first lumen, a second mixing portion inlet in fluid communication with the distal end of the second lumen, and a mixing portion outlet.

[0144] During operation, when the first and second plungers are depressed, a first fluid composition and a second fluid composition are dispensed from a first tube and a second tube, whereby the first and second fluid compositions mix and ultimately crosslink to form a radiopaque crosslinked hydrogel, which is then applied to or within the subject's tissue. For example, the first and second fluid compositions may enter a mixing section from the first and second tubes via a first mixing section inlet and a second mixing section inlet, whereby the first and second fluid compositions mix to form a mixture, which exits the mixing section via a mixing section outlet. In some embodiments, a cannula or catheter is attached to the mixing section outlet, thereby allowing the mixture to be applied to the subject after passing through the cannula or catheter.

[0145] As another example, a first fluid composition may enter the first lumen of a multi-lumen catheter from a first tube outlet, and a second fluid composition may enter the second lumen of the multi-lumen catheter from a second tube outlet. In some embodiments, the first fluid composition and the second fluid composition may enter a mixing section at the distal end of the multi-lumen catheter from the first lumen and the second lumen, respectively, via a first mixing section inlet and a second mixing section inlet, whereby the first fluid composition and the second fluid composition are mixed in the mixing section to form a mixture, which exits the mixing section via a mixing section outlet.

[0146] Regardless of the type of apparatus used to mix the first and second fluid compositions, or how the first and second fluid compositions are mixed, after the mixture of the first and second fluid compositions is formed, the mixture is initially in a fluid state and can be applied to a subject (e.g., a mammal, particularly a human) using a variety of techniques. Alternatively, the first and second fluid compositions can be applied to the subject independently, and the fluid mixture of the first and second fluid compositions is formed inside or on the surface of the subject. In either method, the fluid mixture of the first and second fluid compositions is formed and used in a variety of medical procedures.

[0147] For example, in applications such as the treatment of diseases and cancers, as well as the repair and regeneration of tissues, the first fluid composition and the second fluid composition or a mixture thereof can be injected to provide spacers between tissues; the first fluid composition and the second fluid composition or a mixture thereof can be injected (e.g., in the form of blister) to provide reference markers or organ markers; the first fluid composition and the second fluid composition or a mixture thereof can be injected for tissue enlargement or regeneration (including cosmetic tissue enlargement); the first fluid composition and the second fluid composition or a mixture thereof can be injected as fillers or substitutes for soft tissues; the first fluid composition and the second fluid composition or a mixture thereof can be injected to provide mechanical support for damaged tissues; the first fluid composition and the second fluid composition or a mixture thereof can be injected as scaffolds; the first fluid composition and the second fluid composition or a mixture thereof can be injected as embolic compositions; the first fluid composition and the second fluid composition or a mixture thereof can be injected for seminal vesicle occlusion; the first fluid composition and the second fluid composition or a mixture thereof can be injected as lifting agents for the removal of internal cysts; and / or the first fluid composition and the second fluid composition or a mixture thereof can be injected as carriers of therapeutic agents. The first fluid composition and the second fluid composition, or a fluid mixture thereof, can also be injected into the left atrial appendage during a left atrial appendage occlusion procedure, or injected for the occlusion of an atrial septal defect. In some embodiments, the first fluid composition and the second fluid composition, or a fluid mixture thereof, can be injected into the left atrial appendage after the introduction of an occlusion device (such as the Watchman® left atrial appendage occlusion device available from Boston Scientific Corporation).

[0148] Upon application of the compositions disclosed herein (either as a first fluid composition and a second fluid composition mixed in vivo, or as a fluid mixture of the first fluid composition and the second fluid composition), a radiopaque cross-linked hydrogel is ultimately formed at the application site.

[0149] During and / or after application, the compositions of this disclosure can be imaged using suitable imaging techniques. Typically, the imaging techniques are X-ray based techniques, such as computed tomography or X-ray fluorescence fluoroscopy, or near-IR fluorescence spectroscopy techniques.

[0150] As can be seen from the above, the compositions disclosed herein can be used in a variety of medical procedures, including: procedures for implanting a reference marker comprising a crosslinked product of a first fluid composition and a second fluid composition; procedures for implanting a tissue regeneration scaffold comprising a crosslinked product of a first fluid composition and a second fluid composition; procedures for implanting a tissue support comprising a crosslinked product of a first fluid composition and a second fluid composition; procedures for implanting a building agent comprising a crosslinked product of a first fluid composition and a second fluid composition; procedures for implanting an embolization composition comprising a crosslinked product of a first fluid composition and a second fluid composition; procedures for implanting a composition comprising a crosslinked product of a first fluid composition and a second fluid composition to provide seminal vesicle occlusion; procedures for implanting a lifting agent comprising a crosslinked product of a first fluid composition and a second fluid composition; procedures for implanting a left atrial appendage occlusion composition comprising a crosslinked product of a first fluid composition and a second fluid composition; procedures for implanting a depot containing a therapeutic agent comprising a crosslinked product of a first fluid composition and a second fluid composition; procedures for tissue enlargement including implanting a crosslinked product of a first fluid composition and a second fluid composition; and procedures for introducing a crosslinked product of a first fluid composition and a second fluid composition between a first tissue and a second tissue to separate the first tissue from the second tissue.

[0151] The first fluid composition and the second fluid composition, a fluid mixture of the first fluid composition and the second fluid composition, or a crosslinked product of the first fluid composition and the second fluid composition can be injected in combination with a variety of medical procedures including: injection as a septum between the prostate or vagina and rectum in radiotherapy for rectal cancer; injection as a septum between the rectum and prostate in radiotherapy for prostate cancer; subcutaneous injection for palliative treatment of prostate cancer; transurethral or submucosal injection for female stress urinary incontinence; intravesical injection for urinary incontinence; intrauterine injection for Asherman's syndrome; submucosal injection for anal incontinence; percutaneous injection for heart failure; intramyocardial injection for heart failure and dilated cardiomyopathy; injection for closure of atrial septal defects; injection for seminal vesicle occlusion; transendocardial injection for myocardial infarction; intra-articular injection for osteoarthritis; and injection for spinal cord injury. Spinal injections for spinal fusion and spinal, maxillofacial and orthopedic trauma surgery; spinal injections for posterolateral lumbar fusion; intradiscal injections for degenerative disc diseases; inter-pancreatic and duodenal injections for pancreatic cancer imaging; resection bed injections for oropharyngeal cancer imaging; peritumoral injections for bladder cancer imaging; submucosal injections for gastrointestinal tumors and polyps; visceral pleural injections for lung biopsies; renal injections for type 2 diabetes and chronic kidney disease; renal cortical injections for chronic kidney disease with congenital abnormalities from the kidneys and urethra; intravitreal injections for neovascular age-related macular degeneration; intratympanic injections for sensorineural hearing loss; and dermal injections to correct wrinkles, creases and folds, signs of facial fat loss, volume reduction, superficial to deep contour defects, correction of depressed skin scars, perioral wrinkles, lip augmentation, facial fat atrophy, and to stimulate natural collagen production.

[0152] In the case of in vitro formation, the radiopaque cross-linked hydrogel can be in any desired form, including plates, cylinders, coatings, or granules. In some embodiments, the radiopaque cross-linked hydrogel is dried and then granulated into particles of suitable size. Granulation can be performed by any suitable method, such as by grinding (including cryogenic grinding), homogenization, crushing, milling, or pulverizing. The particles can be sorted and separated using sieving or other known techniques. The size of the radiopaque cross-linked hydrogel particles formed using the above and other techniques can vary considerably, for example, with an average size of 50 to 950 micrometers.

[0153] In addition to the radiopaque crosslinked hydrogels described above, the radiopaque crosslinked hydrogel compositions according to this disclosure may contain other agents, including therapeutic agents, imaging agents, colorants, tension modifiers, suspending agents, wetting agents, and pH adjusters as described above.

[0154] In various embodiments, kits are provided that include one or more delivery devices for delivering a radiopaque cross-linked hydrogel to a subject. Such systems may include one or more of the following: a syringe tubing, which may or may not contain the radiopaque cross-linked hydrogel as described herein; a vial, which may or may not contain the radiopaque cross-linked hydrogel as described herein; a needle; a flexible tube (e.g., adapted for fluid connection of the needle to a syringe); and an injectable liquid, such as water for injection, physiological saline, or phosphate-buffered saline. Whether provided as a syringe, vial, or other reservoir, the radiopaque cross-linked hydrogel may be provided in a dry form (e.g., powder form) or in a ready-for-injection form, such as an injectable hydrogel form (e.g., a suspension of radiopaque cross-linked hydrogel particles).

[0155] Figure 7 A syringe 10 is shown, which provides a reservoir for the radiopaque crosslinked hydrogel composition as described above. The syringe 10 may include a tube 12, a plunger 14, and one or more stoppers 16. The tube 12 may include, for example, a Luer adapter (or other suitable adapter / connector) at its distal end 18 for attachment to an injection needle 50 via a flexible conduit 29. The proximal end of the conduit 29 may include a suitable connector 20 for receiving the tube 12. In other instances, the tube 12 may be directly connected to the injection needle 50. The syringe tube 12 can serve as a reservoir for containing the radiopaque crosslinked hydrogel composition 15 for injection via the needle 50.

[0156] The radiopaque cross-linked hydrogel compositions described herein can be used for a variety of purposes.

[0157] For example, in applications such as the treatment of diseases and cancers, as well as tissue repair and regeneration, radiopaque cross-linked hydrogel compositions can be injected to provide spacers between tissues; radiopaque cross-linked hydrogel compositions (e.g., in the form of bubbles) can be injected to provide reference markers; radiopaque cross-linked hydrogel compositions can be injected for tissue enlargement or regeneration; radiopaque cross-linked hydrogel compositions can be injected as fillers or substitutes for soft tissues; radiopaque cross-linked hydrogel compositions can be injected to provide mechanical support for damaged tissues; radiopaque cross-linked hydrogel compositions can be injected as scaffolds; and / or radiopaque cross-linked hydrogel compositions can be injected as carriers of therapeutic agents.

[0158] During and / or after application, the radiopaque crosslinked hydrogel compositions of this disclosure can be imaged using suitable imaging techniques.

[0159] As described above, the radiopaque cross-linked hydrogel composition of this disclosure can be used in a variety of medical procedures, including: procedures for implanting a reference marker comprising a radiopaque cross-linked hydrogel; procedures for implanting a tissue regeneration scaffold comprising a radiopaque cross-linked hydrogel; procedures for implanting a tissue support comprising a radiopaque cross-linked hydrogel; procedures for implanting a tissue filler comprising a radiopaque cross-linked hydrogel; procedures for implanting a therapeutic reservoir comprising a radiopaque cross-linked hydrogel; tissue enlargement procedures including implantation of a radiopaque cross-linked hydrogel; and procedures for introducing a radiopaque cross-linked hydrogel between a first tissue and a second tissue to separate the first tissue from the second tissue.

[0160] Radiopaque cross-linked hydrogel compositions can be injected in conjunction with a variety of medical procedures, including: injections as a septum between the prostate or vagina and rectum in radiotherapy for rectal cancer; injections as a septum between the rectum and prostate in radiotherapy for prostate cancer; subcutaneous injections for palliative treatment of prostate cancer; transurethral or submucosal injections for female stress urinary incontinence; intravesical injections for urinary incontinence; intrauterine injections for Asherman's syndrome; submucosal injections for anal incontinence; percutaneous injections for heart failure; intramyocardial injections for heart failure and dilated cardiomyopathy; transendocardial injections for myocardial infarction; intra-articular injections for osteoarthritis; spinal injections for spinal fusion and spinal, maxillofacial, and orthopedic trauma surgery; and spinal injections for posterolateral lumbar fusion. Intradiscal injection for degenerative disc diseases; interdural injection for pancreatic and duodenal imaging of pancreatic cancer; resection bed injection for oropharyngeal cancer imaging; peritumoral injection for bladder cancer imaging; submucosal injection for gastrointestinal tumors and polyps; visceral pleural injection for lung biopsy; renal injection for type 2 diabetes and chronic kidney disease; renal cortical injection for chronic kidney disease with congenital abnormalities from the kidneys and urethra; injection for seminal vesicle occlusion; intravitreal injection for neovascular age-related macular degeneration; intratympanic injection for sensorineural hearing loss; correction of wrinkles, creases and folds; signs of facial fat loss; volume reduction; superficial to deep contour defects; correction of depressed skin scars; perioral wrinkles; lip augmentation; facial fat atrophy; dermal injection to stimulate natural collagen production.

[0161] The radiopaque crosslinked hydrogel compositions according to this disclosure include smooth compositions for medical applications, compositions for the release of therapeutic agents (e.g., by including one or more therapeutic agents in the matrix of the crosslinked hydrogel), and implants (which may be formed in vitro or in vivo) (e.g., compositions used as tissue markers, compositions acting as spacers to reduce the side effects of off-target radiotherapy, cosmetic compositions, etc.).

Claims

1. A system comprising (a) a reactive polymer comprising a plurality of first hydrophilic polymer segments and a plurality of first reactive moieties, (b) a reactive multifunctional compound comprising a plurality of second reactive moieties, and (c) gold nanoparticles functionalized with a plurality of second hydrophilic polymer segments.

2. The system of claim 1, wherein the reactive polymer is a multi-arm polymer comprising three or more polymer arms connected to a core region, each arm comprising one of the plurality of first hydrophilic polymer segments and one of the plurality of first reactive portions.

3. The system according to any one of claims 1-2, wherein the reactive polymer is a multi-arm polymer comprising three or more polymer arms connected to a core region, each arm comprising a cyclic anhydride residue located between a first hydrophilic polymer segment and a first reactive portion.

4. The system according to any one of claims 1-3, wherein the first hydrophilic polymer segment is selected from poly(epoxyalkylene) segments, polysaccharide segments, polyoxazoline segments, polydioxanone segments, polypeptide segments, and polyvinyl alcohol segments.

5. The system according to any one of claims 1-4, wherein each of the plurality of first hydrophilic polymer segments contains 10 to 1000 monomer residues.

6. The system according to any one of claims 1-5, wherein the longest size of the gold nanoparticles is in the range of 1 nm to 2 micrometers.

7. The system according to any one of claims 1-6, wherein the plurality of second hydrophilic polymer segments are selected from poly(epoxyalkylene) segments, polysaccharide segments, polyoxazoline segments, polydioxanone segments, polypeptide segments, and polyvinyl alcohol segments.

8. The system according to any one of claims 1-7, wherein the plurality of second reactive portions are linked to polyol residues or polycarboxylic acid residues.

9. The system according to any one of claims 1-8, wherein the plurality of second reactive portions are linked to the polyfunctional compound via hydrolyzable ester groups.

10. The system according to any one of claims 1-9, wherein the plurality of first reactive portions comprise a cyclic imide ester group and the plurality of second reactive portions comprise a primary amine group, a thiol group, or a hydroxyl group, or wherein the plurality of first reactive portions comprise a primary amine group, a thiol group, or a hydroxyl group and the plurality of second reactive portions comprise a cyclic imide ester group.

11. The system according to any one of claims 1-9, wherein the plurality of first reactive portions comprise a strained alkynyl group and the plurality of second reactive portions comprise an azide group, or wherein the plurality of first reactive portions comprise an azide group and the plurality of second reactive portions comprise a strained alkynyl group.

12. The system according to any one of claims 1-9, wherein the plurality of first reactive portions comprise a tonicinyl group and the plurality of second reactive portions comprise a tetrazinyl group, or wherein the plurality of first reactive portions comprise a tetrazinyl group and the plurality of second reactive portions comprise a tonicinyl group.

13. The system according to any one of claims 1-12, further comprising a delivery device.

14. A crosslinked hydrogel comprising gold nanoparticles according to any one of claims 1-12, wherein the gold nanoparticles are retained in a crosslinking reaction product of a reactive polymer and a multifunctional compound according to any one of claims 1-12.

15. The cross-linked hydrogel of claim 14, wherein the cross-linked hydrogel is in the form of injectable particles.